QUANTA LiteÂ® MPO SC ELISA - inova

More documents

Recommendations

Info

Plan de plaque1 2 3 4 5 6 7 8 9 10 11 12ABCDEFGHRésumé de la procédure1. Déposer 100µL de chaque calibrateur, contrôle et échantillon dilué au 1:101 dans les puitsappropriés.Incuber 30 minutes. Laver.2. Ajouter 100µL de conjugué par puits.Incuber 30 minutes. Laver.3. Ajouter 100µL de substrat par puits.Incuber 30 minutes.4. Ajouter 100µL de solution d’arrêt par puits.Mesurer l’absorbance à 450nm.QUANTA Lite et INOVA QUANTA Lite et INOVA Diagnostics sont des marques déposées Copyright 2012 Tous droits réservés ©6
Références1. Ramirez G, Khamashata M. A and Hughes G. R. V. The ANCA test: Its clinical relevance. Annals of theRheumatic Diseases; 1990; 49: 741-742.2. Noel L. H et al. Antineutrophil cytoplasm antibodies: Diversity and clinical applications. Advances inNephrology; 1993; 22: 237-267.3. Gross W. L, Schmitt W. H and Csernok E. ANCA and associated diseases: Immunodiagnostic andpathogenic aspects. Clin. Exp. Immunol.; 1993;91: 1-12.4. Gross W. L, Hauschild S and Mistry N. The clinical relevance of ANCA in vasculitis. Clin. Exp. Immunol;1993; 93: 8-11.5. Hagen E. C et al. Development and standardisation of solid phase assays for the detection of antineutrophilcytoplasmic antibodies (ANCA). A report on the second phase of an international co- operativestudy on the standardisation of ANCA assays. Journal of Immunological Methods, 1996; 196: 1-15.6. Savage C. O. S. The interaction of endothelial cells with inflammatory cells in vasculitis. SarcoidosisVasculitis and Diffuse Lung Diseases; 1996; 13: Special Issue7. Bosch X. et al. Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidasespecificity in anti-glomerular basement membrane disease. Clinical Nephrology; 1991; 3: 107-113.8. Cohen J. W, Tervaert et al. Autoantibodies against myeloid lysosomal enzymes in crescenticglomerulonephritis. Kidney International; 1990; 37: 799-806.9. Rump J. A. et al. P-ANCA of undefined specificity in ulcerative colitis: correlation to disease activity andtherapy. Advances in Experimental Medicine and Biology; 1993; 336: 507-512.10. Lesavre P. et al. Atypical autoantigen targets of perinuclear antineutrophil cytoplasm antibodies (P-ANCA):Specificity and clinical associations. Journal of Autoimmunity; 1993; 6: 185-195.11. Broekroelofs J, MD et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients withInflammatory Bowel Disease. Digestive Diseases and Sciences, 1994; 3: 545-549.12. Nölle B, Specks U. et al. Anti-cytoplasmic antibodies: their immunodiagnostic value in Wegener’sgranulomatosis. Ann Intern Med, 1989; 111: 28-40.13. Protein Reference Unit Handbook of Autoimmunity (3rd Edition) 2004 Ed A Milford, Ward. J. Sheldon, GDWild. Publ. PRU Publications, Sheffield. 14.14. Biosafety in Microbiological and Biomedical Laboratories. Center for Disease Control/National Institute ofHealth, 2007, Fifth Edition.Fabricant:INOVA Diagnostics, Inc.9900 Old Grove RoadSan Diego, CA 92131United States of AmericaTechnical Service (U.S. & Canada Only) :877-829-4745Technical Service (Outside the U.S.) :00+ 1 858-805-7950support@inovadx.comReprésentant Autorisé:Medical Technology Promedt Consulting GmbHAltenhofstrasse 80D-66386 St. Ingbert, GermanyTel.: +49-6894-581020Fax.: +49-6894-581021www.mt-procons.com624655FRA July 2012Revision 37
Page 1 and 2: QUANTA Lite ®Uniquement pour “Di
Page 3 and 4: ProcédureMatériel fourni• MPO S
Page 5: Performances SpécifiquesPrécision

QUANTA LiteÂ® MPO SC ELISA - inova

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?